What is the primary mechanism of action of PROTAC (proteolysis-targeting chimaera) molecules?

Recruiting target proteins to E3 ligases for degradation

Replacing mutated genes with healthy genetic material

Blocking the active site of a protein to inhibit its function

Enhancing the immune system's ability to detect cancer cells

Which of the following is a significant advantage of PROTACs over conventional small-molecule inhibitors?

They can act as catalysts to degrade multiple copies of a target protein

They are smaller and easier for the body to absorb

They do not rely on cellular machinery to function

They only require a single dose for a lifetime cure

Daily

250 words

4/10
Rating

7 July 2026

FDA approval for vepdegestrant cancer therapy

The topic introduces PROTAC technology, a significant advancement in biotechnology that serves as a relevant example for questions regarding emerging medical technologies and their applications in healthcare.

Notes

On May 1, the U.S. FDA approved vepdegestrant for patients with ESR1-mutated, ER-positive, and HER2-negative advanced breast cancer.
Vepdegestrant is the first FDA-approved therapy based on PROTAC (proteolysis-targeting chimaera) technology.
PROTACs function by recruiting target proteins to E3 ligases, which are enzymes involved in the cell's natural protein degradation process.
Unlike conventional drugs that block protein activity, PROTACs act as catalysts to remove the entire protein from the cell.
A single PROTAC molecule can degrade multiple copies of a target protein, potentially allowing for lower dosages.
PROTACs can target 'undruggable' proteins that lack suitable binding sites for traditional inhibitors.
Development challenges include the large, complex structure of PROTACs, which affects absorption, and the potential for reduced efficacy at high concentrations.
Current PROTACs primarily utilize two E3 ligases, though human cells contain over 600, limiting tissue specificity.
Over 40 PROTAC candidates are currently in clinical trials, targeting over 200 proteins for cancer, neurodegenerative diseases, and inflammatory conditions.

Questions

What is PROTAC technology, and how does it differ from conventional drug mechanisms in the treatment of advanced cancers? 150 words

Attempt this — 150 words in 8 min

0 / 150 words 8:00
Discuss the potential of targeted protein degradation in addressing 'undruggable' diseases. What are the primary technical and biological challenges that must be overcome to make PROTAC-based therapies a standard clinical practice? 250 words

Attempt this — 250 words in 11 min

0 / 250 words 11:00

Prelims

What is the primary mechanism of action of PROTAC (proteolysis-targeting chimaera) molecules?

Which of the following is a significant advantage of PROTACs over conventional small-molecule inhibitors?

Syllabus

Topics

Science & Technology

Sources

Why FDA nod for vepdegestrant is a major shift in cancer therapy

250words.in · https://250words.in/daily/2026-07-07/fda-approval-for-vepdegestrant-cancer-therapy